Review
Open access
Aug 2026
HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial
Background: Cutaneous squamous cell carcinoma (CSCC) accounts for 20% of all cutaneous cancers. Systemic treatment options for advanced CSCC (aCSCC) include immunotherapy, chemotherapy, and epidermal growth factor receptor (EGFR)-targeted therapy, although their efficacy is limited. HLX07 is a novel anti-EGFR antibody...
Chang-Xing Li, Kang Zeng, Dong-Yuan Zhu et al.
· Therapeutic Advances in Medi... · 0 citations